Nutriband Advances Opioid Patch Technology with Potential Abuse-Deterrent Solution
Nutriband is making significant progress toward commercializing its AVERSA Fentanyl technology, partnering with Kindeva Drug Delivery to develop a potentially groundbreaking opioid pain patch with abuse-deterrent properties.
Nutriband Inc. is moving closer to introducing a novel opioid pain patch that could revolutionize pain management and drug safety. The company's AVERSA Fentanyl technology represents a potential breakthrough in addressing the ongoing opioid crisis by incorporating abuse-deterrent properties into transdermal pain medication.
Through a strategic partnership with Kindeva Drug Delivery, a leading contract development and manufacturing organization, Nutriband is advancing the development and potential commercialization of its innovative drug delivery system. CEO Gareth Sheridan highlighted the company's focused efforts to scale up manufacturing processes and bring the AVERSA technology closer to market readiness.
The significance of this development lies in its potential to provide a safer alternative to traditional opioid pain medications. By integrating abuse-deterrent mechanisms into the patch design, Nutriband aims to reduce the risk of medication misuse and addiction, a critical concern in current pain management practices.
As the pharmaceutical industry continues to seek solutions to the opioid epidemic, Nutriband's approach could represent an important step in developing more responsible pain treatment options. The company's progress suggests a promising pathway toward addressing both patient pain management needs and the broader public health challenges associated with opioid medications.